Pan-Cancer Proteomic and Transcriptomic Meta-Analysis of PD-1/PD-L1 Signaling Reveals Predictive Biomarkers for Anti-PD-1 Therapy in Lung Cancer
Journal of Proteome Research · 2026
DOI: 10.1021/acs.jproteome.5c01238 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Journal of Proteome Research, 2026. Verfasst von Yuying Suo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Analytical Research Center for Organic and Biological Molecules, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Biomarkers, Tumor, Lung Neoplasms, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 89 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Shanghai Rising-Star Program.
Abstract (Originalsprache)
Programmed death-ligand 1 (PD-L1) is an immune checkpoint molecule that enables tumor cells to escape immune surveillance, and its blockade by immune checkpoint inhibitors has become an effective therapeutic strategy in various cancers. Previous studies have primarily focused on genomic and transcriptomic features within specific cancer types, while proteomic analyses remain relatively limited. Here, we conducted a comprehensive pan-cancer meta-analysis encompassing 12 human cancer types to systematically characterize PD-1/PD-L1 signaling pathways at both the proteomic and transcriptomic levels. We observed clear cancer-type-specific patterns of PD-1/PD-L1 expression. Pathway-crosstalk analyses further revealed multiple pathways and phosphorylation events influencing PD-1/PD-L1 activity. Immune-infiltration profiling identified MMP9+ neutrophils as key immune subsets associated with PD-1/PD-L1 pathway activity. Using proteomic data, we constructed a PD-L1-centered protein-protein interaction network and identified TAP proteins as potential predictive biomarkers in small-cell lung cancer. We also established a biomarker signature capable of predicting clinical response to anti-PD-1 therapy in non-small-cell lung cancer and validated this gene set in two independent previously published cohorts. Finally, we developed an interactive web application (https://yuyingsuo-simm.shinyapps.io/PD-L1_Profiling/) to facilitate visualization of PD-L1 features and exploration of its associations with genes and pathways of interest.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Analytical Research Center for Organic and Biological Molecules, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
- University of the Chinese Academy of Sciences, Beijing 100049, China.
- School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China.
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Shanghai Rising-Star Program
- Chinese Academy of Sciences
- Shanghai Leading Talent Program of Eastern Talent Plan
Zitieren
APA
Suo, Y., Song, Y., Zhou, H., & Liu, Q. (2026). Pan-Cancer Proteomic and Transcriptomic Meta-Analysis of PD-1/PD-L1 Signaling Reveals Predictive Biomarkers for Anti-PD-1 Therapy in Lung Cancer. Journal of Proteome Research. https://doi.org/10.1021/acs.jproteome.5c01238
Vancouver
Suo Y, Song Y, Zhou H, Liu Q. Pan-Cancer Proteomic and Transcriptomic Meta-Analysis of PD-1/PD-L1 Signaling Reveals Predictive Biomarkers for Anti-PD-1 Therapy in Lung Cancer. Journal of Proteome Research. 2026. doi:10.1021/acs.jproteome.5c01238
BibTeX
@article{Suo2026,
author = {Suo, Yuying and Song, Yuanli and Zhou, Hu and Liu, Qian},
title = {Pan-Cancer Proteomic and Transcriptomic Meta-Analysis of PD-1/PD-L1 Signaling Reveals Predictive Biomarkers for Anti-PD-1 Therapy in Lung Cancer},
journal = {Journal of Proteome Research},
year = {2026},
doi = {10.1021/acs.jproteome.5c01238}
}
EUVIMED